IDEXX Q3 2026 Earnings: Recurring Diagnostics Growth Lifts Margins

IDEXX Laboratories (NASDAQ: IDXX) reported Q3 2026 revenue of $1.214 billion, up 10% year over year on both a reported and organic basis, while diluted EPS rose 18% to $4.01. For the quarter ended September 30, 2026, CAG Diagnostics recurring revenue grew 11%, helping expand gross margin by 110 basis points and operating margin by 100 basis points. IDEXX raised its full-year revenue and EPS outlooks but lowered its operating-margin range to incorporate acquisition-related effects.

Core Financial Results

Gross profit and operating profit grew faster than revenue, reflecting higher recurring diagnostic volumes, operational productivity, and net price realization. Reported operating expenses increased 10% as IDEXX expanded commercial capabilities, invested in innovation, and absorbed acquisition-related costs.

Organic growth and comparable growth are non-GAAP measures. Comparable results exclude currency effects and specified unusual or nonrecurring items.

Business and Segment Performance

The Companion Animal Group remained the main growth engine. CAG Diagnostics recurring revenue increased 11% on both a reported and organic basis, including 13% reported and 14% organic growth internationally and 10% growth in the U.S. on both measures.

VetLab consumables produced the strongest product-level growth. IDEXX attributed the increase to new customers, an 11% expansion in its global premium instrument installed base, higher utilization supported by recent product launches, and net price gains.

IDEXX placed more than 1,900 inVue Dx analyzers during the quarter, bringing the installed base to nearly 11,000 instruments. Veterinary software, services, and imaging also benefited from installations of the ImageVue DR50 Plus system.

Recurring Diagnostics Growth Outpaced Expense Growth

Revenue increased 10%, while gross profit rose 12% and operating profit advanced 13%. IDEXX linked this operating leverage to recurring-revenue volume growth, productivity initiatives, and net price realization. These factors more than offset the effect of higher spending on commercial capabilities, innovation, and acquisitions during the quarter.

On a comparable basis, gross margin expanded 90 basis points to 62.7%, while operating margin increased 60 basis points to 32.7%. Comparable operating expenses rose 11%, slightly faster than reported expenses because currency reduced reported expense growth.

Reported EPS included a $0.03-per-share non-operating gain on an equity investment, a $0.01 tax benefit from share-based compensation, and a $0.04 benefit from year-over-year currency changes. IDEXX also absorbed acquisition effects during the period.

2026 Guidance

IDEXX raised its full-year revenue outlook by $32 million at the midpoint and increased the EPS midpoint by $0.25, primarily reflecting stronger CAG Diagnostics recurring revenue performance. The revised revenue range includes $5 million associated with the CoVet acquisition. At the same time, the company lowered its operating-margin range by 20 basis points at both ends to account for acquisition-related effects.

The outlook assumes foreign exchange will add approximately 0.7 percentage points to revenue growth, 30 basis points to operating-margin growth, and $0.25 to EPS.

Management Commentary

President and CEO Mike Erickson attributed the quarter to commercial execution and IDEXX’s innovation strategy. Management highlighted inVue Dx with fine-needle aspiration capabilities and the expansion of Cancer Dx into a multi-cancer panel as tools intended to help veterinary practices detect disease earlier and improve efficiency.

IDEXX also acquired CoVet, an AI clinical assistant designed to support veterinary team productivity and diagnostics utilization. The acquisition contributes to revenue guidance but is also among the factors incorporated into the lower operating-margin outlook.

Recent Insider Transactions

The supplied six-month insider summary classifies 4,568 shares across 11 transactions as purchases and 2,203 shares in one transaction as sales, resulting in net purchases of 2,365 shares. The records below are the latest entries with transaction details; all were listed as direct ownership.

These records describe the transactions but do not establish insiders’ views about IDEXX’s valuation or future performance.

Risks Investors Should Watch

• Diagnostic volume sustainability: Recurring diagnostic growth depended on same-store volume expansion, new customers, and higher instrument utilization. A slowdown in any of these drivers could affect revenue and margin leverage.
• Rapid assay volume pressure: Rapid assay revenue grew only 1% because price benefits offset lower testing volumes, making this product category a relative weak point.
• Acquisition costs and integration: IDEXX lowered its operating-margin outlook after incorporating acquisition effects. CoVet integration and related spending could influence the timing of margin expansion.
• Higher operating investment: Comparable operating expenses increased 11% as IDEXX funded commercial and innovation initiatives. Continued expense growth could limit operating leverage if revenue growth moderates.
• Currency sensitivity: The full-year outlook includes favorable foreign-exchange assumptions, including an estimated $0.25 EPS benefit. Different exchange-rate movements could change reported growth and profitability.

Summary

IDEXX’s Q3 2026 results were driven by double-digit recurring diagnostics growth, particularly in VetLab consumables and reference laboratory services. That mix, together with productivity and pricing, allowed profit and margins to grow faster than revenue despite increased investment and acquisition costs. The raised revenue and EPS outlooks point to continued operating momentum, while the reduced margin range makes acquisition integration, expense growth, and diagnostic volumes the main items to monitor.